WELLTUSS EXP  - dihydrocodeine bitartrate, pseudoephedrine hydrochloride and guaifenesin syrup 
Prasco Laboratories


WellTuss EXP


Antitussive/Decongestant/Expectorant for oral administration.

Each 5 mL (one teaspoonful) contains:

Dihydrocodeine Bitartrate………….7.5 mg

(WARNING – May be habit forming)

Pseudoephedrine Hydrochloride…….15 mg

Guaifenesin………………………..100 mg

WellTuss EXP is sugar, alcohol, and dye free.

Dihydrocodeine Bitartrate is an antitussive with the chemical name (Morphinan-6-ol, 4,5-epoxy-3-methoxy-17-methyl-(5α, 6α)-2,3-dihydroxy-butanedioate (1:1) (base). It has the following structural formula:


Guaifenesin is an expectorant. Chemically, it is 3-(2-methoxyphenoxy)-1,2-propanediol and has the following structural formula:


Pseudoephedrine Hydrochloride is a decongestant having the chemical name Benzenemethanol, -[1-(methylamino)ethyl]-,[S-(R*,R*)]-hydrochloride.

It has the following structural formula:


In addition, WellTuss EXP contains the following inactive ingredients: benzoic acid, bitter masking agent, caramel coloring, glycerin, menthol, propylene glycol, saccharin sodium, sorbitol, vanillin, and water.


Dihydrocodeine is a semi-synthetic narcotic analgesic/antitussive related to codeine, with multiple actions qualitatively similar to those of codeine: the most prominent of these involve the central nervous system and organs with smooth muscle components.

Guaifenesin is an expectorant, which increases respiratory tract fluid secretions and helps to loosen phlegm and bronchial secretions. By reducing the viscosity of secretions, guaifenesin increases the efficiency of the cough reflex and of ciliary action in removing accumulated secretions from the trachea and bronchi.

Pseudoephedrine Hydrochloride is a sympathomimetic amine, which acts predominately on alpha-receptors and has little action on beta-receptors. It therefore functions as an oral nasal decongestant with minimal CNS stimulation.


WellTuss EXP is indicated for the temporary relief of nasal congestion and dry, non-productive cough associated with upper respiratory tract infections and allergies.


This combination product is contraindicated in patients with hypersensitivity to dihydrocodeine, codeine, or any of the active or inactive components listed above, or in any situation where opioids are contraindicated including significant respiratory depression (in unmonitored settings or in the absence of resuscitation equipment), acute or severe bronchial asthma or hypercapnia, and paralytic ileus. Sympathomimetic agents are contraindicated in patients with severe hypertension, severe coronary artery disease, patients with narrow angle glaucoma, bronchial asthma, urinary retention, peptic ulcer, and during an asthmatic attack. This product is contraindicated in women who are pregnant.


General: Considerable caution should be exercised in patients with hypertension, diabetes mellitus, ischemic, heart disease, hyperthyroidism, increased intraocular pressure, and prostatic hypertrophy. The elderly (60 years and older) are more likely to exhibit adverse reactions.

Usage in Ambulatory Patients: Dihydrocodeine may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.

Respiratory Depression: Respiratory depression is the most dangerous acute reaction produced by opioid agonist preparations, although it is rarely severe with usual doses. Opioids decrease the respiratory tidal volume, minute ventilation, and sensitivity to carbon dioxide. Respiratory depression occurs most frequently in elderly or debilitated patients, usually after large initial doses in non-tolerant patients, or when opioids are given in conjunction with other agents that depress respiration. This combination product should be used with caution in patients with significant chronic obstructive pulmonary disease or cor pulmonale and in patients with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or respiratory depression.

Hypertensive Effect: Dihydrocodeine, like all opioid analgesics, may cause hypotension in patients whose ability to maintain blood pressure has been compromised by a depleted blood volume or who received concurrent therapy with drugs such as phenothiazine or other agents which compromise vasomotor tone.

WellTuss EXP may product orthostatic hypotension in ambulatory patients. This combination product should be administered with caution to patients with circulatory shock since vasodilation produced by the drug may further reduce cardiac output and blood pressure.

Dependence: Dihydrocodeine can produce drug dependence of the codeine type and has the potential of being abused. This product should be prescribed and administered with the appropriate degree of caution (See Drug Abuse and Dependence section).


General: This combination product should be used with caution in elderly or debilitated patients or those with any of the following conditions: adrenocortical insufficiency (e.g., Addison’s disease); asthma; central nervous system depression or coma; chronic obstructive pulmonary disease; decreased respiratory reserve (including emphysema, severe obesity, cor pulmonale, or kyphoscoliosis); delirium tremens; diabetes; head injury; hypotension; hypertension; increased intracranial pressure; myxedema or hypothyroidism; prostatic hypertrophy or urethral structure; and toxic psychosis. The benefits and risks of opioids in patients taking monoamine oxidase inhibitors and in those with a history of drug abuse should be carefully considered. This combination product may aggravate convulsions in patients with convulsive disorders, and like all opioids, may induce or aggravate seizures in some clinical settings.

Drug Interactions: General: Sympathomimetic amines may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids.

Other CNS Depressants: Patients receiving other opioid analgesics, sedatives or hypnotics, muscle relaxants, general anesthetics, centrally acting antiemetics, phenothiazines or other tranquilizers, or alcohol concomitantly with this product may exhibit additive depressant effects on the central nervous system. When such combination therapy is contemplated, the dose of one or both agents should be reduced. Concomitant use of dihydrocodeine with alcohol and other CNS depressants may have an additive effect.

Monoamine Oxidase Inhibitors: Dihydrocodeine, like all opioids, interact with monoamine oxidase inhibitors causing central nervous system excitation and hypertension. MAO inhibitors and beta-adrenergic blockers increase the effects of sympathomimetics.

Information for Patients: Patients receiving WellTuss EXP should be given the following information:

Patients should be advised that WellTuss EXP is a potential drug of abuse. They should protect it from theft, and it should never be given to anyone other than the individual for whom it was prescribed.

Pregnancy: Teratogenic Effects – Pregnancy Category C: Animal reproduction studies have not been conducted with WellTuss EXP. It is also not known whether this combination product can cause fetal harm when administered to pregnant women or can effect reproduction capacity in males and females. This combination product should be given to a pregnant woman only if clearly needed, especially during the first trimester.

Nonteratogenic Effects: Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting, and fever. The intensity of the syndrome does not always correlate with the duration of the maternal opioid use or dose. There is no consensus on the best method of managing withdrawal. Chlorpromazine 0.7-1.0 mg/kg q6h, Phenobarbital 2mg/kg q6h, and paregoric 2-4 drops/kg q4h, have been used to treat withdrawal symptoms in infants. The duration of therapy is 4 to 28 days, with dosages decreased as tolerated.


WellTuss EXP is not recommended for use by women during and immediately before labor and delivery because oral opioids may cause respiratory depression in the newborn.


This product is not recommended for use in children under two years of age. Children under two years may be more susceptible to respiratory arrest, coma, and death. Very young children may be more susceptible to the effects, especially the vasopressor effects of sympathomimetic amines. Appropriate studies on the relationship of age to the effects of guaifenesin have not been performed in the pediatric population. However, no pediatric specific problems have been documented to date.


WellTuss EXP should be given with caution to the elderly.

Hepatic Impairment: WellTuss EXP should be given with caution to patients with hepatic insufficiency since dihydrocodeine is metabolized by the liver the effects of this combination product should be monitored closely in such patients.

Renal Impairment: WellTuss EXP should be used with caution and at reduced dosage in the presence of impaired renal function.

Pancreatic/biliary Tract Disease: Opioids may cause spasms of the sphincter of Oddi and should be used with caution in patients with biliary tract disease, including pancreatitis.


The most frequently observed adverse reaction with dihydrocodeine include light-headedness, dizziness, drowsiness, headache, fatigue, sedation, sweating, nausea, vomiting, constipation, pruritus, and skin reactions. With the exception of constipation, tolerance develops to most of these effects. Other reactions that have been observed with dihydrocodeine or opioids include respiratory depression, orthostatic hypotension, cough suppression, confusion, diarrhea, miosis, abdominal pain, dry mouth, indigestion, anorexia, spasm of biliary tract, and urinary retention. Physical and psychological dependence are possibilities. Hypersensitivity reactions (including anaphylactoid reactions), hallucinations, vivid dreams, granulomatous interstitial nephritis, severe narcosis and acute renal failure have been reported rarely during dihydrocodeine administration. Other reactions observed with the ingredients in WellTuss EXP inclue lassitude, nausea, giddiness, dryness of mouth, blurred vision, cardiac palpitations, flushing, increased irritability or excitement (especially in children).


This combination product is subject to the provisions of the Controlled Substances Act and has been placed in Schedule III. Dihydrocodeine can produce drug dependence of the codeine type and therefore has the potential of being abused. Psychological dependence, physical dependence, and tolerance may develop upon repeat administration of dihydrocodeine, and it should be prescribed and administered with the same degree of caution appropriate to the use of other opioid medications. Symptoms of dihydrocodeine withdrawal consist of irritability, restlessness, insomnia, diaphoresis, anxiety, and palpitations.


An overdose of WellTuss EXP is a potentially lethal poly-drug overdose situation, and consultation with a regional Poison Control Center is recommended. A listing of the Poison Control Centers can be found in a standard reference such as the Physician’s Desk Reference.

Signs and Symptoms: Symptoms of an overdose include pinpoint pupils, respiratory depression, extreme somnolence progressing to stupor, loss of consciousness or coma, skeletal muscle flaccidity, cold and clammy skin and other symptoms common with narcotic overdosage. Convulsions, cardiovascular collapse, and death may occur. A single case of acute rhabdomyolysis associated with an overdose of dihydrocodeine has been reported.

Recommended Treatment: Immediate treatment of an overdose of WellTuss EXP includes support of cardiovascular function and measures to reduce further drug absorption. Vomiting should be induced with syrup of ipecac. If the patient is alert and has adequate laryngeal reflexes, oral activated charcoal should follow. The first dose should be accompanied by an appropriate cathartic. Gastric lavage may be necessary. Hypotension is usually hypovolemic and should be treated with fluids. Endotracheal intubation and artificial respiration may be necessary. The pure opioid antagonist naloxone or nalmexone is a specific antidote against respiratory depression that results from opioid overdose Opioid antagonists should not be given in the absence of clinically significant respiratory or circulatory depression secondary to opioid overdose. They should be administered cautiously to persons who are known, or suspected to be, physically dependent on any opioid agonist including dihydrocodeine. In such cases, an abrupt or complete reversal of opioid effects may precipitate an acute abstinence syndrome. The prescribing information for the specific opioid antagonist should be consulted for details of their proper use.


Adults and Adolescents over 12 years: 1 to 2 teaspoonfuls (5 mL to 10 mL)

Children 6 to under 12 years of age: ½ to 1 teaspoonful (2.5 mL to 5 mL)

Children 2 to under 6 years of age: ¼ to ½ teaspoonful (1.25 mL to 2.5 mL)

These doses may be given every 4 to 6 hours as needed. Not recommended for children under 2 years of age.


WellTuss EXP is supplied as an amber syrup with a fruity aroma in 16 oz. (473 mL) bottles (NDC 66993-501-57).


Store at controlled room temperature 59°-86°F (15°-30°C).

Dispense in tight, light resistant container as defined in the USP/NF.

Rx Only

Manufactured for:

Prasco Laboratories

Cincinnati, Ohio 45249


Manufactured by:

Sovereign Pharmaceuticals, Ltd.

Forth Worth, TX 76118

Iss. 07/04




dihydrocodeine bitartrate, pseudoephedrine hydrochloride, guaifenesin   syrup
Product Information
Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 66993-501
Route of Administration ORAL DEA Schedule CIII    
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Inactive Ingredients
Ingredient Name Strength
Product Characteristics
Color BROWN (amber) Score     
Shape Size
Flavor FRUIT (fruity aroma) Imprint Code
# NDC Package Description Multilevel Packaging
1 66993-501-57 473 mL In 1 BOTTLE None

Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
Unapproved drug other 08/31/2004 12/31/2006

Labeler - Prasco Laboratories (065969375)
Name Address ID/FEI Operations
Sovereign Pharmaceuticals, Ltd. 623168267 MANUFACTURE
Revised: 02/2011 Prasco Laboratories